GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Resonance Health Ltd (ASX:RHT) » Definitions » ROE % Adjusted to Book Value

Resonance Health (ASX:RHT) ROE % Adjusted to Book Value : -3.95% (As of Dec. 2023)


View and export this data going back to 1987. Start your Free Trial

What is Resonance Health ROE % Adjusted to Book Value?

Resonance Health's ROE % for the quarter that ended in Dec. 2023 was -11.29%. Resonance Health's PB Ratio for the quarter that ended in Dec. 2023 was 2.86. Resonance Health's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -3.95%.


Resonance Health ROE % Adjusted to Book Value Historical Data

The historical data trend for Resonance Health's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resonance Health ROE % Adjusted to Book Value Chart

Resonance Health Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.22 -1.33 0.90 -4.17 -3.96

Resonance Health Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.69 -6.76 -1.83 -5.45 -3.95

Competitive Comparison of Resonance Health's ROE % Adjusted to Book Value

For the Health Information Services subindustry, Resonance Health's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Resonance Health's ROE % Adjusted to Book Value Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Resonance Health's ROE % Adjusted to Book Value falls into.



Resonance Health ROE % Adjusted to Book Value Calculation

Resonance Health's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-7.56% / 1.91
=-3.96%

Resonance Health's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-11.29% / 2.86
=-3.95%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Resonance Health ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Resonance Health's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Resonance Health (ASX:RHT) Business Description

Traded in Other Exchanges
N/A
Address
141 Burswood Road, Level 1, Burswood, WA, AUS, 6100
Resonance Health Ltd is a healthcare company specializing in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its product includes FerriScan, a non-invasive liver diagnostic technology used for the measurement of iron in the liver, and HepaFat-Scan. The company's operating segment includes Services; Research and Development and Corporate. It generates maximum revenue from the Services segment. Geographically, it derives a majority of its revenue from North America and Europe-Middle-East-Africa (EMEA) and also has a presence in Asia/Pacific.

Resonance Health (ASX:RHT) Headlines

No Headlines